Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.54 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680911 | 0.88 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1598049 | 0.85 | PIK3CG (0.70) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1598246 | 0.83 | PIK3CD (0.68) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL681687 | 0.81 | PIK3CD (0.66) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL681908 | 0.79 | PIK3CD (0.76) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL681818 | 0.77 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1598366 | 0.77 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1599331 | 0.76 | PIK3CD (0.70) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1597951 | 0.74 | PIK3CG (0.84) | PIK3CGPIK3CDPIK3C2B | |
| SCHEMBL12599287 | 0.73 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CHEN YI | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3C2B 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.